MAPT and Alzheimer disease: In this report, we tested for the first time the immunogenicity and therapeutic efficacy of AV-1980R formulated with AdvaxCpG adjuvant (AV-1980R/A) in the PS19 tau transgenic mouse model and demonstrated that the vaccine generated extremely high titers of anti-tau antibodies that recognized pathological tau in human AD brain tissue and reduced the accumulation of total and certain phospho-tau epitopes in the brains of vaccinated PS19 transgenic mice.